Skip to main content

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and / or TGR-1202 Trials

Trial Status: Enrolling by Invitation

This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and / or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.

Inclusion Criteria

  • Subjects must be currently receiving treatment with ublituximab and/or TGR-1202 on a previously approved protocol.
  • Subjects must have completed at least 6 cycles of therapy on their current protocol.

Exclusion Criteria

  • Subject progressed while receiving therapy with ublituximab and/or TGR-1202 while participating in their immediate previous trial.


University of Nebraska Medical Center
Status: ACTIVE

Trial Phase Phase II

Trial Type Treatment

Lead Organization
TG Therapeutics Inc

  • Primary ID UTX-TGR-501
  • Secondary IDs NCI-2019-00763
  • ID NCT03207256